Literature DB >> 12711290

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

V F Cocquyt1, P N Blondeel, H T Depypere, M M Praet, V R Schelfhout, O E Silva, J Hurley, R F Serreyn, K K Daems, S J P Van Belle.   

Abstract

AIM: Preoperative chemotherapy (PCT) is used in primary breast cancer, to facilitate breast conservative surgery (BCS). Clinical and pathologic responses are important prognostic parameters. Biologic markers are needed to individualize treatment. PATIENTS AND METHODS: One hundred and thirty-five patients with breast carcinoma were treated with PCT, followed by surgery and adjuvant therapy. Clinical response and pathological complete response (pCR), biological markers and type of surgery were compared between invasive ductal (IDC) and invasive lobular carcinoma (ILC).
RESULTS: Overall response (OR) for IDC was 75% compared to 50% for ILC (P=0.0151). Pathological CR was 15% for IDC and 0% for ILC (P=0.0066). Fifty-six percent of the responding patients had BCS, in contrast with 16% of the non-responders. BCS was performed in 50% of patients with IDC, in 38% of the patients with ILC. Salvage surgery was more necessary in ILC (19%) compared to IDC (4%) (P=0.0068). Patients with ILC were more frequently ER-positive and HER-2 negative than patients with IDC.
CONCLUSIONS: Clinical and pathological responses are lower in ILC compared to IDC. After PCT, patients with large ILC should preferably be offered mastectomy with immediate breast reconstruction. However, PCT still remains valuable to evaluate tumor response and biologic factors in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711290     DOI: 10.1053/ejso.2002.1404

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  20 in total

1.  Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Authors:  Jae-Heon Jeong; So-Youn Jung; In Hae Park; Keun Seok Lee; Han-Sung Kang; Seok Won Kim; Youngmee Kwon; Eun A Kim; Kyung Lan Ko; Byung-Ho Nam; Seeyoun Lee; Jungsil Ro
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

2.  Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.

Authors:  Judy C Boughey; Jamie Wagner; Betsy J Garrett; Lori Harker; Lavinia P Middleton; Gildy V Babiera; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2009-03-12       Impact factor: 5.344

Review 3.  Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

Authors:  Philippe L Bedard; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

4.  The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Jaime A Pardo; Betty Fan; Alessandra Mele; Stephanie Serres; Monica G Valero; Isha Emhoff; Amulya Alapati; Ted A James
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

5.  Invasive lobular carcinoma predicts micrometastasis in breast cancer.

Authors:  Sarah M Gainer; Ashutosh K Lodhi; Anirban Bhattacharyya; Savitri Krishnamurthy; Henry M Kuerer; Anthony Lucci
Journal:  J Surg Res       Date:  2012-03-28       Impact factor: 2.192

6.  Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.

Authors:  Tadahiko Shien; Sadako Akashi-Tanaka; Kunihisa Miyakawa; Takashi Hojo; Chikako Shimizu; Kunihiko Seki; Masashi Ando; Tsutomu Kohno; Naruto Taira; Hiroyoshi Doihara; Noriyuki Katsumata; Yasuhiro Fujiwara; Takayuki Kinoshita
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

7.  The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Authors:  M E Straver; E J Th Rutgers; S Rodenhuis; S C Linn; C E Loo; J Wesseling; N S Russell; H S A Oldenburg; N Antonini; M T F D Vrancken Peeters
Journal:  Ann Surg Oncol       Date:  2010-04-06       Impact factor: 5.344

8.  Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Authors:  Esther H Lips; Rita A Mukhtar; Christina Yau; Jorma J de Ronde; Chad Livasy; Lisa A Carey; Claudette E Loo; Marie-Jeanne T F D Vrancken-Peeters; Gabe S Sonke; Donald A Berry; Laura J Van't Veer; Laura J Esserman; Jelle Wesseling; Sjoerd Rodenhuis; E Shelley Hwang
Journal:  Breast Cancer Res Treat       Date:  2012-09-08       Impact factor: 4.872

9.  Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

Authors:  Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

10.  Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

Authors:  Jamie Wagner; Judy C Boughey; Betsy Garrett; Gildy Babiera; Henry Kuerer; Funda Meric-Bernstam; Eva Singletary; Kelly K Hunt; Lavinia P Middleton; Isabelle Bedrosian
Journal:  Am J Surg       Date:  2009-04-10       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.